Paclitaxel for injection (PAC) is a new breed of anti-microtubule drugs developed by Bristol-Myers Squibb Company of America. Different from vinblastine, its mechanism of action is to combine with microtubule protein, form untypical framework of microtubule in the metabolic period to prevent the physical disaggregating of normal microtubule. It restricts quick division tumor cells in this framework firmly. and at last, tumor cells apoptosis because the copy is limited. Applied as a kind of broad-spectrum anti-tumor drugs, its therapeutic index is quite high.

Paclitaxel is generally applied to cure ovarian cancer, breast cancer, lung cancer, malignant melanoma and so on. It is effective to solid tumors such as esophageal carcinoma, pate tumors, gastric cancers etc.

Paclitaxel has been listed in the catalogue of national essential drugs and national essential medical insurance drugs.